The clinical significance of autoantibodies in gastrointestinal malignancies: an overview

Saif, Muhammad Wasif; Zalonis, Antonis; Syrigos, Kostas

doi:10.1517/14712598.7.4.493

Cited by 15 publications

(10 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, anti-calreticulin antibody positivity did not correspond fully with tumour markers (AFP, CEA, Ca 19-9), serum biochemical markers (albumin, bilirubin, aspartate aminotransferase/alanine aminotransferase, alpha-amylase) or with the presence of metastasis, age, gender or body mass index. Similar observations have been made in the case of anti-p53 antibodies [20].…”

Section: Discussionsupporting

confidence: 86%

“…This variance is caused probably by different genetic, biological and pathological backgrounds as well as the immune status of the patients. Despite this fact, the incidence of serum anti‐calreticulin antibodies in patients with HCC (IgA, IgG) and GBA (IgG) is relatively high and is comparable with autoantibodies against carcinoembryonic antigen in gastrointestinal malignancies [20]. Interestingly, 47–63% of patients with gastrointestinal malignancies (PACA, CRA, HCC) were seropositive for IgA and/or IgG anti‐calreticulin antibodies.…”

Section: Discussionmentioning

confidence: 99%

“…carcinoembryonic antigen (CEA), p53, survivin, livin, mucins, Fas, dsDNA, ssDNA, HER-2/neu, cancer/testes antigens, etc. [14][15][16][17][18][19][20]. Interestingly, constitutive overexpression of calreticulin seems to be a common event in cells from various tumour types including colorectal adenocarcinoma, breast carcinoma and hepatocellular carcinoma [21][22][23].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Calreticulin is a B cell molecular target in some gastrointestinal malignancies

Pekáriková

Sánchez

Palová-Jelínková

et al. 2009

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryCalreticulin, upon translocation to the cell surface, plays a critical role in the recognition of tumour cells and in experimentally induced cellular antitumour immunity. However, less is known about anti-calreticulin antibodies and their role in malignancies. Using enzyme-linked immunosorbent assay (ELISA), we found immunoglobulin (Ig)A and/or IgG anti-calreticulin antibodies in sera of approximately 63% of patients with hepatocellular carcinoma (HCC), 57% of patients with colorectal adenocarcinoma (CRA) and 47% of patients with pancreatic adenocarcinoma (PACA), while healthy controls, patients with viral hepatitis C and with chronic pancreatitis reached only 2%, 20% and 31% seropositivity, respectively. We found significantly elevated mean levels of IgA anti-calreticulin antibodies (P < 0·001) in patients with HCC (78·7 Ϯ 52·3 AU, mean Ϯ standard deviation), PACA (66·5 Ϯ 30·9 AU) and CRA (61·8 Ϯ 25·8 AU) when compared to healthy controls (41·4 Ϯ 19·2 AU). Significantly elevated mean levels of IgG anti-calreticulin antibodies (P < 0·001) were detected in patients with HCC (121·9 Ϯ 94·2 AU), gall bladder adenocarcinoma (118·4 Ϯ 80·0 AU) and PACA (88·7 Ϯ 55·6 AU) when compared to healthy controls (56·7 Ϯ 22·9 AU). Pepscan analysis revealed a large number of antigenic epitopes of calreticulin recognized by both IgA and IgG antibodies of patients with HCC and PACA, indicating robust systemic immune response. Moreover, significantly elevated levels of antibodies against peptide KGEWKPRQIDNP (P < 0·001) in these patients, tested by ELISA, confirmed the distinct character of antibody reactivity against calreticulin. The high occurrence and specificity of serum anticalreticulin autoantibodies in the majority of patients with some gastrointestinal malignancies provide the evidence for their possible clinical relevance.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Calreticulin is a B cell molecular target in some gastrointestinal malignancies

Pekáriková

Sánchez

Palová-Jelínková

et al. 2009

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…CEA-IgM has been already distributed for years in Europe and it had some results. The difference of sensitivity might be due to the racial difference of producing IgM, which is assumed to belong to natural antibody to cancer 11,12) , although the direct evidence has not been proved yet. For example, Japanese might have higher titer of natural antibody to CEA than European.…”

Section: Discussionmentioning

confidence: 99%

Titration of serum CEA, p53 antibodies and CEA-IgM complexes in 142 patients with colorectal cancer and 150 healthy blood donors.

Kojima

Matsui

Fujimitsu

et al. 2011

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

Background:The early detection of colorectal cancer is important issue for improving the survival rate. Although fecal occult-blood testing and Carcinoembryonic antigen (CEA) in serum is widely used for noninvasive screen method, it has limited sensitivity. Methods: 142 patients with primary colorectal cancer who underwent surgery and 150 healthy volunteers were enrolled in this study. 37 of the tumors (26%) were Stage I, 34 (24%) were Stage II, 58 (41%) were Stage III, 12 (9%) were Stage IV. In each serum sample, CEA, p53 antibodies, and CEA-IgM complexes were measured. Results: The diagnostic sensitivity with CEA (cut-off: 5 ng/ml) and p53 antibodies (cut-off: 3.0 U/ml) was 48% (68/142), Stage I 16% (6/37), Stage II 56% (19/34), Stage III 53% (31/58), and Stage IV 92% (12/13), while false positive rate was 7% (10/150). Because the sensitivity of CEA-IgM (cut-off: 150 AU/ml) was low, three tests combination did not much increase the overall sensitivity. Conclusions: The sensitivity of CEA-IgM for detecting colon cancer was lower than expected from previous study. As for the specificity of p53-antibodies, because its sensitivity is preserved with cut-off at 3.0 U/ml, re-evaluation of present cutoff level (1.3 U/ml) seemed to be needed.

show abstract

“…The presence of anti-livin antibodies was for the first time detected by Yagihashi et al 7 in patients with malignancies of the intestinal tract and later in those with breast and lung cancer. [8][9][10] The authors used an enzyme immunoassay to detect antibodies, a similar method to our radioimmunoassay described previously.…”

Section: Resultsmentioning

confidence: 99%

Anti‑livin antibodies in Hashimoto thyroiditis

Baumann-Antczak¹,

Kosowicz²,

Zamysłowska³

et al. 2012

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

INTROduCTION Livin belongs to the family of apoptosis inhibitors. High livin expression is observed in malignancies of the gastrointestinal tract, lungs, breast, and kidneys, but it is not present in differentiated adult tissues. In some malignant processes, anti-livin antibodies are present.ObjECTIvEs The aim of the study was to evaluate the prevalence of anti-livin antibodies in Hashimoto thyroiditis, a disease characterized by rapid and widespread thyrocyte apoptosis. PATIENTs ANd mEThOdsThe study comprised 65 women with Hashimoto thyroiditis and the control group of 40 healthy women. In the majority of the patients, clinical manifestations of hypothyroidism were observed; all patients had high levels of serum antithyroid peroxidase antibodies. A solid-phase radioimmunoassay in livin-coated polyethylene tubes using 125I-labeled protein A was used to determine anti-livin antibodies.REsuLTs Significant amounts of anti-livin antibodies were reported in 18 patients (26.8%); 3 patients (4.6%) had borderline antibody levels; while in controls only 1 patient was positive (2.5%, P <0.0001).CONCLusIONs In Hashimoto thyroiditis, an autoimmune process is more general and involves numerous autoantibodies including an antibody against apoptosis inhibitor -livin. Anti-livin antibodies cannot serve only as a marker of malignancy because they are also present in autoimmune processes. KEy wORdsanti-livin antibodies, Hashimoto thyroiditis

show abstract

The clinical significance of autoantibodies in gastrointestinal malignancies: an overview

Cited by 15 publications

References 142 publications

Calreticulin is a B cell molecular target in some gastrointestinal malignancies

Calreticulin is a B cell molecular target in some gastrointestinal malignancies

Titration of serum CEA, p53 antibodies and CEA-IgM complexes in 142 patients with colorectal cancer and 150 healthy blood donors.

Anti‑livin antibodies in Hashimoto thyroiditis

Contact Info

Product

Resources

About